Management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of wt reduction based on exercise, diet & behaviour modification in obese patients w/ BMI of ≥30 kg/m2. Overwt patients w/ lower BMI (25-29.9 kg/m2) which increases the risk of morbidity from a number of disorders.
Should be taken with food: Take at breakfast. Avoid taking near bedtime. Swallow whole, do not chew/crush.
Contraindications
Hypersensitivity to sympathomimetic drugs. Pulmonary artery HTN; existing heart valve abnormalities or heart murmurs; moderate to severe arterial HTN; cerebrovascular disease; severe cardiac disease including arrhythmias, advanced arteriosclerosis; hyperthyroidism; agitated states or history of psychiatric illnesses including anorexia nervosa & depression; glaucoma; history of drug/alcohol abuse or dependence. Concomitant treatment w/ MAOI or w/in 14 days following their administration.
Short-term monotherapy for the management of exogenous obesity. Not recommended w/ drug products for wt loss; SSRIs (eg, fluoxetine, sertraline, paroxetine), ergot-like drugs & clomipramine; fenfluramine or dexfenfluramine. Primary pulmonary HTN; require medical review at least every 3 mth. Patients w/ mild HTN; established CAD; receiving psychotropic drugs including sedatives, agents w/ sympathomimetic activity & antihypertensives; epileptics. Response to insulin & oral hypoglycemic agents may vary due to alterations in dietary regimes. Wt loss should be gradual & controlled in obese patients undergoing treatment. May impair ability to perform activities requiring mental alertness eg, driving & operating machinery. Not recommended during pregnancy & lactation. Not recommended for childn <12 yr & elderly.
Sign Out
